ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

The researchers will measure a child’s individual exposure to air pollutants for 24-hours-a-day for four weeks using digital devices clipped to his or her clothing. By comparing air pollution exposure to periodic daily measurements of breathing capacity, the researchers will assess the impact of air pollution on asthma. The researchers also will evaluate the effect of stress conditions within the children’s lives through interviews with participant families and measurement of stress hormones, in order to determine whether or not those children with higher stress levels have more severe responses to air pollution.

The team includes six investigators from the Environmental and Occupational Health Sciences Institute, a joint institute of UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, and members of the Ironbound Community Corporation, the neighborhood’s leading social services agency, which will participate in conducting the study.

Source UMDNJ-Robert Wood Johnson Medical School

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s